secwatch.observer — SEC 8-K summary
======================================

Issuer:     Claritev Corp (CTEV)
CIK:        0001793229
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001793229-25-000106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Claritev Q1 revenue $231.3M (-1.4% YoY); net loss $71.3M vs $539.7M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Revenue $231.3M, down 1.4% from $234.5M; net loss improved to $71.3M from $539.7M.
- Adjusted EBITDA $142.1M (61.4% margin) vs $146.8M in prior year.
- Free cash flow negative $(68.9)M vs positive $19.2M; cash $23.1M.
- Reaffirmed FY2025 guidance: revenue (2)% to flat, Adj. EBITDA margin 62.5%-63.5%, FCF $(65)-$(75)M.
- Announced strategic alliances with Oracle, J2 Health, and Burjeel Holdings; new Chief Medical and AI officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/0001793229-25-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1793229/000179322925000106/ctev-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001793229-25-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer